Advertisement


Michael Unterhalt, MD, on Mantle Cell Lymphoma: Long-Term Follow-up Results

2017 ASH Annual Meeting

Advertisement

Michael Unterhalt, MD, of the University Hospital Grosshadern, discusses study findings on rituximab maintenance after first-line immunochemotherapy among older patients who are not candidates for autologous stem cell transplantation (Abstract 153).



Related Videos

Lymphoma

Tycel J. Phillips, MD, on Intravascular DLBCL: Study of Patient Features and Outcomes

Tycel J. Phillips, MD, of the University of Michigan Medical School, discusses the findings of the largest retrospective study to date of patients with intravascular diffuse large ...

Lymphoma

Jia Ruan, MD, on Mantle Cell Lymphoma: Study Results on Lenalidomide and Rituximab

Jia Ruan, MD, of NewYork-Presbyterian/Weill Cornell Medical Center, discusses a 5-year follow-up analysis that showed lenalidomide and rituximab as initial treatment achieved a hig...

Multiple Myeloma

Maria-Victoria Mateos, MD, PhD, on Multiple Myeloma: Results From the ALCYONE Trial

Maria-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, discusses phase III study findings on daratumumab plus bortezomib, melphalan, and prednisone vs bortezomib,...

Lymphoma

Gilles A. Salles, MD, PhD, on Follicular Lymphoma: Long-Term Results From the PRIMA Trial

Gilles A. Salles, MD, PhD, of the Université de Lyon, discusses study findings on rituximab maintenance after induction immunochemotherapy and the significant long-term progression...

Lymphoma

Andrew D. Zelenetz, MD, PhD, and Sattva S. Neelapu, MD, on NHL: Results From the ZUMA-1 Trial

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Sattva S. Neelapu, MD, of The University of Texas MD Anderson Cancer Center, discuss lo...

Advertisement

Advertisement



;
Advertisement